PuSH - Publikationsserver des Helmholtz Zentrums München

Stemmer, K. ; Finan, B.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; Müller, T.D.

Insights into incretin-based therapies for treatment of diabetic dyslipidemia.

Adv. Drug Deliv. Rev. 159, 34-53 (2020)
Postprint DOI
Open Access Green
Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Diabetes ; Dyslipidemia ; Incretins ; Lipoproteins ; Obesity; Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Dependent Insulinotropic Polypeptide; Lipoprotein-lipase Activity; Low-density-lipoprotein; Dipeptidyl Peptidase-4 Inhibitor; Impaired Glucose-tolerance; Brown Adipose-tissue; High-fat; Receptor Agonist
ISSN (print) / ISBN 0169-409X
e-ISSN 1872-8294
Zeitschrift Advanced Drug Delivery Reviews
Quellenangaben Band: 159, Heft: , Seiten: 34-53 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Förderungen German Center for Diabetes Research (DZD e.V.)
Helmholtz Alliance ICEMED
Helmholtz Initiative on Personalized Medicine iMed by Helmholtz Association
Helmholtz cross-program topic "Metabolic Dysfunction"
German Research Foundation Grants
European Research Council ERC AdG HypoFlam
Alexander von Humboldt Foundation